BCL2 and neoplasm: In 2017, Demaria et al. reported that the clearance of non-malignant senescent cells following doxorubicin treatment, in studies utilizing either a transgenic (p16-3MR) mouse model or the Bcl-2 family-targeting agent, navitoclax, resulted in less severe bone-marrow suppression, a decrease in cardiac dysfunction, a reduction in the development of metastases, and interference with tumor recurrence [55].